Plain-English translation of NCT06982079 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called dapagliflozin can help protect kidney function in people with advanced chronic kidney disease (stages 4–5) who haven't started dialysis yet. Dapagliflozin was originally created to help control blood sugar in diabetes, but recent research suggests it may also protect the kidneys. This study wants to see if the medication works in patients with very serious kidney disease—a group that hasn't been thoroughly studied before.
Most large kidney disease studies have excluded people with the most advanced kidney damage, so doctors don't yet know if this medication can help the sickest patients. This trial fills that gap by testing whether the treatment can slow kidney decline and help people avoid or delay needing dialysis.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll either receive a daily 10 mg dapagliflozin tablet along with your regular kidney disease treatment, or continue with standard care alone (decided by random assignment). The study will monitor your kidney function and overall health to see whether the medication helps preserve the kidney function you have left and potentially delays the need for dialysis.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
Egypt